← Leaderboards

Merit E Cudkowicz

Massachusetts General Hospital

Google Scholar ↗PubMed ↗ORCID ↗

$97,012,119

Attributed

$115,918,711

Total exposure

32

Grants

15

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $11.2M · FY2005–25

$20M$15M$10M$5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$113,904,272 · 30

FDA$2,014,439 · 2

By mechanism

U01$93,046,483 · 4

R01$7,477,479 · 5

U44$5,635,109 · 1

RC2$3,782,000 · 1

OT2$2,596,654 · 1

M01$1,967,689 · 17

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Maurizio Fava$41,478,557
Brian Jason Wainger$12,066,353
Stephen C. Cannon$14,616,444
Jeevendra Martyn$10,698,401
Marco Luciano Loggia$20,270,265

Others in their field

Top investigators on “Clinical Research”

David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
Sonia M Thomas · Research Triangle Institute$700,865,642
Jeffrey P Krischer · University Of South Florida$611,867,176
Barton F Haynes · Duke University$538,862,577

Research focus

Clinical ResearchClinical TrialsAmyotrophic Lateral SclerosisSafetyDesignEnsureOutcome MeasureProtocols DocumentationHuman SubjectBaseNervous System DisorderAdultDoseLeadHuman Therapy EvaluationPlacebosChronicParticipantRandomizedResourcesProgramsInnovationPlacebo ControlPrincipal Investigator

Grant awards (107)

Clinical Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials (NEXT - CCC)$2,770,869

U01 · FY2025 · NS · contact PI

Gene Therapy Consortium (GTC) for Gene-Based Clinical Trials Conducted within NeuroNEXT$2,134,862

OT2 · FY2025 · NS · contact PI

Clinical Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials (NEXT - CCC)$1,180,472

U01 · FY2025 · NS · contact PI

Gene Therapy Consortium (GTC) for Gene-Based Clinical Trials Conducted within NeuroNEXT$164,828

OT2 · FY2025 · NS · contact PI

Clinical Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials (NEXT - CCC)$2,691,169

U01 · FY2024 · NS · contact PI

Gene Therapy Consortium (GTC) for Gene-Based Clinical Trials Conducted within NeuroNEXT$296,964

OT2 · FY2024 · NS · contact PI

Clinical Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials (NEXT - CCC)$2,835,251

U01 · FY2023 · NS · contact PI

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,393,953

U01 · FY2022 · NS · contact PI

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$613,516

U01 · FY2022 · NS · contact PI

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,402,275

U01 · FY2021 · NS · contact PI

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,395,171

U01 · FY2020 · NS · contact PI

Topiramate as a Disease Altering Therapy for CSPN$874,009

U01 · FY2020 · NS

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,398,805

U01 · FY2019 · NS · contact PI

Topiramate as a Disease Altering Therapy for CSPN$1,847,422

U01 · FY2019 · NS

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,450,857

U01 · FY2018 · NS · contact PI

Topiramate as a Disease Altering Therapy for CSPN$2,219,043

U01 · FY2018 · NS

Tolerability of SRX246 in Huntington's Disease Patients$764,163

U44 · FY2018 · NS

Topiramate as a Disease Altering Therapy for CSPN$2,399,189

U01 · FY2017 · NS

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,322,084

U01 · FY2017 · NS · contact PI

Tolerability of SRX246 in Huntington's Disease Patients$1,480,173

U44 · FY2017 · NS

Tolerability of SRX246 in Huntington's Disease Patients$61,234

U44 · FY2017 · NS

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,618,494

U01 · FY2016 · NS · contact PI

Tolerability of SRX246 in Huntington's Disease Patients$2,214,354

U44 · FY2016 · NS

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,601,373

U01 · FY2015 · NS · contact PI

Tolerability of SRX246 in Huntington's Disease Patients$1,115,185

U44 · FY2015 · NS

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$102,600

U01 · FY2015 · NS · contact PI

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,663,374

U01 · FY2014 · NS · contact PI

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,742,199

U01 · FY2013 · NS · contact PI

Coenzyme Q10 in Huntingtons Disease$1,349,440

U01 · FY2013 · NS · contact PI

Phase II/III Study of Arimoclomol in the Treatment of SOD1 Positive Familial?.$399,424

R01 · FY2013 · FD

Clinical Trial of Ceftriaxone in Subjects with ALS$3,575,101

U01 · FY2012 · NS · contact PI

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,672,682

U01 · FY2012 · NS · contact PI

Coenzyme Q10 in Huntingtons Disease$1,350,086

U01 · FY2012 · NS · contact PI

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$82,476

U01 · FY2012 · NS · contact PI

Clinical Trial of Ceftriaxone in Subjects with ALS$6,688,079

U01 · FY2011 · NS · contact PI

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial$2,740,976

U01 · FY2011 · NS · contact PI

Phase II/III Study of Arimoclomol in the Treatment of SOD1 Positive Familial?.$399,489

R01 · FY2011 · FD

Clinical Trial of Ceftriaxone in Subjects with ALS$6,809,454

U01 · FY2010 · NS · contact PI

Coenzyme Q10 in Huntington's Disease$1,967,943

U01 · FY2010 · NS · contact PI

Generation and Characterization of Amyotrophic Lateral Sclerosis iPS cells$1,837,375

RC2 · FY2010 · NS

Multi-Center Validation of Biomarkers for Motor Neuron Disease$385,307

RC1 · FY2010 · NS

Multi-Center Validation of Biomarkers for Motor Neuron Disease$100,000

RC1 · FY2010 · NS

Generation and Characterization of Amyotrophic Lateral Sclerosis iPS cells$82,000

RC2 · FY2010 · NS

Clinical Trial of Ceftriaxone in ALS$7,298,875

U01 · FY2009 · NS · contact PI

Generation and Characterization of Amyotrophic Lateral Sclerosis iPS cells$1,862,625

RC2 · FY2009 · NS

Coenzyme Q10 in Huntington's Disease$1,487,187

U01 · FY2009 · NS · contact PI

Multi-Center Validation of Biomarkers for Motor Neuron Disease$491,399

RC1 · FY2009 · NS

Clinical Trial of Ceftriaxone in ALS$6,125,934

U01 · FY2008 · NS · contact PI

Coenzyme Q10 in Huntington's Disease$1,184,326

U01 · FY2008 · NS · contact PI

Clinical Trial of Ceftriaxone in ALS$1,000,000

U01 · FY2008 · NS · contact PI

Phase II/III Study of Arimoclomol in the Treatment of SOD1 Positive Familial?.$347,273

R01 · FY2008 · FD

Phase II/III Study of Arimoclomol in the Treatment of SOD1 Positive Familial?.$52,608

R01 · FY2008 · FD

CLINICAL TRIAL: OPEN-LABEL ARIMOCLOMOL EXTENSION PROTOCOL$162

M01 · FY2008 · RR · contact PI

Clinical Trial of Ceftriaxone in ALS$3,000,000

U01 · FY2007 · NS · contact PI

Coenzyme Q10 in Huntington's Disease$1,487,896

R01 · FY2007 · NS · contact PI

DOUBLE BLIND STUDY OF MINOCYCLINE IN HD$411,803

R01 · FY2007 · FD · contact PI

Clinical Trial of Ceftriaxone in ALS$36,450

U01 · FY2007 · NS · contact PI

Clinical Trial of Ceftriaxone in ALS$24,900

U01 · FY2007 · NS · contact PI

SAFETY AND PHARMACOKINETICS STUDY OF ARIMOCLOMOL IN ALS$19,610

M01 · FY2007 · RR · contact PI

MULTI-DOSE PLACEBO-CONTROLLED PHASE I STUDY OF AEOL 10150 IN PATIENTS WITH ALS$12,859

M01 · FY2007 · RR · contact PI

OPEN-LABEL ARIMOCLOMOL EXTENSION PROTOCOL$12,217

M01 · FY2007 · RR · contact PI

Clinical Trial of Ceftriaxone in ALS$8,700

U01 · FY2007 · NS · contact PI

Clinical Trial of Ceftriaxone in ALS$8,250

U01 · FY2007 · NS · contact PI

IDENTIFICATION OF DIAGNOSTIC BIOMARKERS AND THERAPEUTIC AGENTS FOR ALS$7,072

M01 · FY2007 · RR · contact PI

Clinical Trial of Ceftriaxone in ALS$3,113,499

U01 · FY2006 · NS · contact PI

DOUBLE BLIND STUDY OF MINOCYCLINE IN HD$403,842

R01 · FY2006 · FD · contact PI

SAFETY STUDY OF AEOL10150 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS$18,892

M01 · FY2006 · RR · contact PI

SAFETY AND DOSE ESCALATING STUDY OF NAPB IN ALS$15,195

M01 · FY2006 · RR · contact PI

MULTI-DOSE PLACEBO-CONTROLLED PHASE I STUDY OF AEOL 10150 IN PATIENTS WITH ALS$10,679

M01 · FY2006 · RR · contact PI

SAFETY AND PHARMACOKINETICS STUDY OF ARIMOCLOMOL IN ALS$7,393

M01 · FY2006 · RR · contact PI

Coenzyme Q10 in Huntington's Disease$1,175,147

R01 · FY2005 · NS

Metabolomic Signatures in ALS$142,420

R21 · FY2005 · ES

PILOT SAFETY AND TOLERABILITY STUDY OF COQ10 IN HD AND IN NORMAL$9,084

M01 · FY2005 · RR

A CLINICAL TRIAL OF COENZYME Q10 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS$1,434

M01 · FY2005 · RR

HISTAMINE DIHYDROCHLORIDE IN ALS$957

M01 · FY2005 · RR

DETERM OF BIOLOGICAL MRKRS IN CEREBROSPINAL FLD SUBJ W/AMYOTROPHIC LTRAL SCLERO$478

M01 · FY2005 · RR

CLINICAL TRIAL OF CELEBREX IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)$478

M01 · FY2005 · RR

DOUBLE BLIND STUDY OF MINOCYCLINE IN HD$0

R01 · FY2005 · FD

Clinical Trial of Ceftriaxone in ALS$1,580,123

R01 · FY2004 · NS

Metabolomic Signatures in ALS$180,420

R21 · FY2004 · ES

CLINICAL TRIAL OF COENZYME Q10 IN PATIENTS WITH ALS$24,888

M01 · FY2004 · RR

CLINICAL TRIAL OF CELEBREX IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)$11,614

M01 · FY2004 · RR

PILOT SAFETY AND TOLERABILITY STUDY OF CoQ10 IN HD AND IN NORMAL$4,978

M01 · FY2004 · RR

HISTAMINE DIHYDROCHLORIDE IN ALS$2,212

M01 · FY2004 · RR

CLINICAL TRIAL OF TOPIRAMATE IN ALS$61,000

R01 · FY2003 · NS

CLINICAL TRIAL OF TOPIRAMATE IN ALS$262,106

R01 · FY2002 · NS

RMetHuBDNF Intrathecal Infusion in ALS$200,768

M01 · FY2002 · RR

COENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE$200,768

M01 · FY2002 · RR

COENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE$200,768

M01 · FY2002 · RR

Topiramate Clinical Trial in Amyotrophic Lateral Scleros$200,768

M01 · FY2002 · RR

Topiramate Clinical Trial in Amyotrophic Lateral Scleros$200,768

M01 · FY2002 · RR

RMetHuBDNF Intrathecal Infusion in ALS$200,768

M01 · FY2002 · RR

CLINICAL TRIAL OF TOPIRAMATE IN ALS$506,691

R01 · FY2001 · NS

Topiramate Clinical Trial in Amyotrophic Lateral Scleros$200,768

M01 · FY2001 · RR

COENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE$200,768

M01 · FY2001 · RR

RMetHuBDNF Intrathecal Infusion in ALS$200,768

M01 · FY2001 · RR

Topiramate Clinical Trial in Amyotrophic Lateral Scleros$0

M01 · FY2001 · RR

RMetHuBDNF Intrathecal Infusion in ALS$0

M01 · FY2001 · RR

COENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE$0

M01 · FY2001 · RR

CLINICAL TRIAL OF TOPIRAMATE IN ALS$390,077

R01 · FY2000 · NS

RISK FACTORS AND THERAPEUTIC STRATEGIES IN ALS$113,751

K08 · FY2000 · NS

COENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE$575

M01 · FY2000 · RR

RMetHuBDNF Intrathecal Infusion in ALS$0

M01 · FY2000 · RR

RMetHuBDNF Intrathecal Infusion in ALS$0

M01 · FY2000 · RR

COENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE$0

M01 · FY2000 · RR

Topiramate Clinical Trial in Amyotrophic Lateral Scleros$0

M01 · FY2000 · RR

Topiramate Clinical Trial in Amyotrophic Lateral Scleros$0

M01 · FY2000 · RR